Restoration of p53 functions protects cells from concanavalin A-induced apoptosis

Molecular Cancer Therapeutics

Volumn 9, Issue 2, 2010, Pages 471-479

  Ruhul Amin, A R M ^a,c   Thakur, Vijay S ^a   Gupta, Kalpana ^a   Jackson, Mark W ^a   Harada, Hisashi ^d   Agarwal, Mukesh K ^b   Shin, Dong M ^c   Wald, David N ^a   Agarwal, Munna L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Invenio Therapeutics   (United States)

^c EMORY UNIVERSITY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CONCANAVALIN A; PROTEIN P53; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR FKHR; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ACTIVATION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROTECTION; CONTROLLED STUDY; FAMILIAL CANCER; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOGENESIS; MOLECULAR INTERACTION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WILD TYPE; CELL CYCLE; GENE EXPRESSION REGULATION; METABOLISM; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CONCANAVALIN A; FORKHEAD TRANSCRIPTION FACTORS; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 76649132668     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0732     Document Type: Article

References (45)

1. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268:2764-72.
2. Feng L, Lin T, Uranishi H, Gu W, Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 2005;25:5389-95.
3. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805.
4. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31.
5. Carter S, Vousden KH. Modifications of p53: competing for the lysines. Curr Opin Genet Dev 2009;19:18-24.
6. Carr AM. Piecing together the p53 puzzle. Science 2000;287:1765-6.
7. Meek DW. Mechanisms of switching on p53: a role for covalent modification? Oncogene 999;18:7666-75.
8. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1999;10: 1054-72.
9. Hastak K, Agarwal MK, Mukhtar H, Agarwal ML. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 2005;19:789-91.
10. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
11. Agarwal MK, Amin AR, Agarwal ML. DNA replication licensing factor minichromosome maintenance deficient 5 rescues p53-mediated growth arrest. Cancer Res 2007;67:116-21.
12. Hammond EM, Mandell DJ, Salim A, et al. Genome-wide analysis of p53 under hypoxic conditions. Mol Cell Biol 2006;26:3492-504.
13. Ho JS, Ma W, Mao DY, Benchimol S. p53-dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 2005;25:7423-31.
14. Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 2003; 28:63-70.
15. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
16. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009;9:738-48.
17. Zenz T, Häbe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589-97.
18. van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 2007;8:440-50.
19. Arden KC. FoxOs in tumor suppression and stem cell maintenance. Cell 2007;128:235-7.
20. You H, Mak TW. Crosstalk between p53 and FOXO transcription factors. Cell Cycle 2005;4:37-8.
21. You H, Pellegrini M, Tsuchihara K, et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 2006a;203:1657-63.
22. You H, Jang Y, You-Ten AI, et al. p53-dependent inhibition of FKHRL1 in response to DNA damage through protein kinase SGK1. Proc Natl Acad Sci U S A 2004;101:14057-62.
23. You H, Yamamoto K, Mak TW. Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc Natl Acad Sci U S A 2006b;103:9051-6.
24. Akhand AA, Pu M, Du J, et al. Magnitude of protein tyrosine phosphorylation-linked signals determines growth versus death of thymic T lymphocytes. Eur J Immunol 1997;27:1254-9.
25. Tamura T, Ishihara M, Lamphier MS, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995;376:596-9.
26. Fayad R, Sennello JA, Kim SH, Pini M, Dinarello CA, Fantuzzi G. Induction of thymocyte apoptosis by systemic administration of concanavalin A in mice: role of TNF-α, IFN-γ and glucocorticoids. Eur J Immunol 2005;35:2304-12.
27. Zhao R, Guerrah A, Tang H, Zhao ZJ. Cell surface glycoprotein PZR is a major mediator of concanavalin A-induced cell signaling. J Biol Chem 2002;277:7882-8.
28. Amin AR, Paul RK, Thakur VS, Agarwal ML. A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, concanavalin A. Cancer Res 2007;67:5617-21.
29. Lu J, Quearry B, Harada H. p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Lett 2006;580:3539-44.
30. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A 1995;92:8493-7.
31. Hussain SP, Amstad P, He P, et al. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 2004;64:2350-6.
32. McClure JE, McClure JA, Shearer WT. Phosphorylation-associated conformation shift of anti-oncogene phosphoprotein p53 in concanavalin-A activated human T lymphocytes. Biochem Biophys Res Commun 1992;189:1701-8.
33. Milner J. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature 1984;310:143-5.
34. Mosner J, Deppert W. Conformational analysis of p53 in resting and concanavalin A-stimulated mouse lymphocytes. Oncogene 1992;7: 661-6.
35. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 1999;96:857-68.
36. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003;162:613-22.
37. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002;277:47928-37.
38. Kops GJ, Dansen TB, Polderman PE, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002;419:316-21.
39. Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002;295:2450-2.
40. Kops GJ, Medema RH, Glassford J, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 2002b;22:2025-36.
41. Tran H, Brunet A, Grenier JM, et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002;296:530-4.
42. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 2003;10:404-8.
43. Gottifredi V, Karni-Schmidt O, Shieh SS, Prives C. p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Mol Cell Biol 2001;21:1066-76.
44. Lohr K, Moritz C, Contente A, Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 2003;278:32507-16.
45. Shats I, Milyavsky M, Tang X, et al. p53-dependent downregulation of telomerase is mediated by p21/waf1. J Biol Chem 2004;65:4530-43.